Acceleron Pharma (XLRN) Lunch Offers Detail on Luspa Approval Path - Cowen
Tweet Send to a Friend
Cowen analyst Yaron Werber reiterated an Outperform rating and $78.00 price target on Acceleron Pharma (NASDAQ: XLRN) after hosting an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
